PROFILE: Tomas Salmonson, chair of the EMA's CHMP, on European collaboration, being a teenage lifeguard and Persian rugs
This article was originally published in SRA
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is the body that effectively says yes or no to your new drug in Europe. Since September 2012, the committee has been chaired by senior Swedish regulator Tomas Salmonson*. In this profile, by Francesca Bruce, find out what Dr Salmonson thinks of the pharmaceutical industry and what key advice he would give companies looking for regulatory approval… and also how he relaxes, what shaped him growing up and why he thinks his grandfather would be proud of him.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.